Skip to content

infLuence Of anovulaTion and menopaUSe on the course of MS

infLuence Of anovulaTion and menopaUSe on the course of MS - LOTUS-MS

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00031183
Enrollment
1000
Registered
2023-02-16
Start date
2023-05-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35

Interventions

Group 1: Patients with an MS diagnosis who participate in the Multiple Sclerosis Register of the DMSG. These patients are interviewed once using a questionnaire on total oestrogen exposure and tested

Sponsors

Klinik für Neurologie, Universitätsklinikum der Ruhr-Universität Bochum
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Written informed consent for participation in the German Multiple Sclerosis Registry. - Definite MS with determinable course or HIS - Primary residence in Germany - Written informed consent for participation in this study

Exclusion criteria

Exclusion criteria: - MS course not determinable - Lack of capacity to consent

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the time to reach an EDSS score of 4. This score is collected as part of the patients' clinical routines.

Secondary

MeasureTime frame
A secondary endpoint is the time to reach an EDSS of 3 and 6. These values are collected as part of the patients' clinical routines. Another secondary endpoint is time to transition to SPMS and patient performance in SDMT.

Countries

Germany

Contacts

Public ContactKerstin Hellwig

Klinik für Neurologie, Universitätsklinikum der Ruhr-Universität Bochum, St. Josef-Hospital

k.hellwig@klinikum-bochum.de+49234 509 6443

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026